Tags : Natalizumab

Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for

Shots: Sandoz to get WW rights to distribute & commercialize proposed biosimilar natalizumab in all markets following its approval. Polpharma Biologics will be responsible for development, manufacturing and supply of proposed biosimilar natalizumab The focus of the agreement is to expand Novartis/Sandoz’s portfolio across small molecules, complex generics, biosimilars, and innovator therapies with the addition […]Read More